Background: Brain metastases commonly occur in non-small cell lung cancer (NSCLC), and patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor-associated tyrosine kinase, has shown antitumor activity in advanced NSCLC. This study evaluates erlotinib in the treatment for brain metastases from NSCLC.
L ung cancer is one of the most common cancer diagnoses and the leading cause of cancer-related deaths worldwide. 1 Non-small-cell lung cancer (NSCLC) accounts for >85% of lung cancer, and its 5-year survival rate is around 16%. 2 Brain metastases are frequent complications in NSCLC patients, with approximately 25% to 38% developing brain metastases at some point during their disease course. [3] [4] [5] [6] [7] Because of the aging population, the improved ability of neuroimaging modalities to detect smaller lesions, the better treatment of systemic diseases, and the longer survival of NSCLC patients, the incidence of brain metastases is likely to rise. In practice, the occurrence of brain metastases from NSCLC has become a significant challenge. Although a variety of treatment options have been available for the optimal management of disease of the central nervous system (CNS), including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), metastasis resection, and chemotherapy, the survival outcome is disappointing and more effective treatments are urgently needed. Novel therapeutic agents, such as inhibitors of epidermal growth factor receptor-associated tyrosine kinase (EGFR-TKI) with erlotinib and gefitinib, demonstrate durable responses in some advanced NSCLC patients. [8] [9] [10] Although the activity of gefitinib against brain metastases from NSCLC has been documented, [11] [12] [13] [14] the information about the effectiveness of erlotinib in this setting is insufficient. The purpose of this retrospective study was to assess the antitumor efficacy and tolerability of erlotinib for brain metastases from NSCLC.
PATIENTS AND METHODS

Patients
From January 2007 to June 2009, a total of 185 NSCLC patients with brain metastases were screened in the Respiratory Department, Shanghai Chest Hospital. Among these patients, 49 once received erlotinib treatment. However, of the 49 patients, 5 were given erlotinib during or shortly after intracranial irradiation and not included in the analysis in consideration of the influence by irradiation; 4 patients receiving other chemotherapeutic agents concurrently were also excluded. Therefore, 40 patients who began erlotinib treatment due to progressive or recurrent brain metastases after failure in previous treatment were eligible for assessment in this retrospective study. The diagnosis of NSCLC was confirmed pathologically, and brain metastases were detected by magnetic resonance imaging or contrast-enhanced computed tomography (CT). Nonsmokers were defined as those who had smoked <100 cigarettes in their lifetime. Multiple brain metastases were defined as 2 or more brain lesions. Extracranial diseases included primary lung tumor and extracranial metastases. At the initiation of erlotinib, baseline evaluations included medical history, an Easten Cooperative Oncology Group performance status (PS), blood cell count, serum biochemistry profile, chest radiographs or CT scan, abdominal ultrasound or CT scan, and radionuclide bone scan. Recursive portioning analysis (RPA) was used to identify these patients into 3 classes. 15 EGFR mutations were retrospectively examined by directing sequencing in 9 patients whose surgical specimens from primary lung tumors were available.
Treatment
All patients enrolled were given orally erlotinib 150 mg daily and continued treatment until disease progression, death, or unacceptable toxicity. CNS-directed therapy (eg, SRS) was not performed in these patients in case of progressive CNS disease during erlotinib treatment. Patients receiving other chemotherapeutic agents or thoracic radiation concurrently were excluded.
Response Assessment and Toxicity Evaluation
Tumor responses were first assessed by radiologic images (including brain and extracranial lesions) after 4 and 8 weeks of erlotinib treatment, and patients were followed up monthly thereafter; the follow-up images of the brain and extracranial lesions were routinely performed every 2 months or when clinically indicated. Repeat CNS imaging was usually prompted by new neurological signs and symptoms. Tumor response was assessed as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), in accordance with the standard Response Evaluation Criteria in Solid Tumors. 16 The objective response rate (ORR) was defined as CR plus PR. The disease control rate (DCR) was defined as the best tumor response of CR, PR, or SD. Tumor responses for intracranial and extracranial diseases were evaluated separately. Adverse events were graded according to a modified 2.0 version of the National Cancer Institute Common Toxicity Criteria.
Statistical Analysis
SPSS software version 11.0 for Windows was used for statistical analysis. The association between tumor response and clinical characteristics was evaluated using the Pearson w 2 test. The variables under consideration included age, sex, smoking history, histology, PS, number of brain metastases (single or multiple), and RPA class. Survival curves were calculated using the Kaplan-Meier method. Multivariate survival analysis was performed using Cox proportional hazard method by entering all significant variables from the univariate analysis. Statistical significance was defined as P < 0.05.
Progression-free survival (PFS) was measured from the beginning date of oral erlotinib to the date of the first documented progression or death. Overall survival (OS) was determined from the date of starting oral erlotinib to the date of death from any cause or the last follow-up. Patients who had not died or progressed at the time of the final analysis were censored at the date of last contact.
RESULTS
Patient Characteristics
Patient characteristics included: median age, 54 years (range, 27 to 77 y); 34 males (85%) and 6 females (15%); 25 smokers (62.5%) and 15 nonsmokers (37.5%); 30 adenocarcinoma cases (75%) and 10 nonadenocarcinoma cases (25%) (including 7 squamous cell carcinoma, 2 large cell carcinoma, and 1 not otherwise specified); 32 cases (80%) with PS 0 to 2 and 8 cases (20%) with PS 3 to 4; single intracranial lesion in 13 cases (32.5%) and multiple intracranial lesions in 27 cases (67.5%); 4 cases (10%) with RPA class I, 28 (70%) with RPA class II, and 8 (20%) with RPA class III. All patients enrolled had extracranial diseases. All patients had previously undergone both intracranial irradiation (30 with WBRT and 10 with SRS followed by WBRT) and chemotherapy (13 with r3cycles, 22 with 4 to 5 cycles, and 5 with Z6 cycles) ( Table 1 ). Of the 9 patients with analysis of EGFR mutations, 5 were found to harbor activating mutations, including 3 exon 19 deletions and 2 exon 21 L858R mutations, whereas 4 had negative mutational status.
Response Assessment
All patients were evaluated for responses of both intracranial and extracranial diseases to erlotinib. As for intracranial diseases, PR was observed in 4 patients (10%), SD in 21 patients (52.5%), and PD in 15 patients (37.5%), yielding an ORR of 10% and a DCR of 62.5% ( Table 2) . As for extracranial diseases, DCR was observed in 17 patients (42.5%) (3 PRs + 14 SDs) and PD in 23 patients (57.5%) ( Table 2 ). In addition, among 25 patients with DC regarding intracranial lesions, 14 (56%) exhibited DC in extracranial lesions (3 PRs+11 SDs), whereas among 15 patients with PD regarding intracranial lesions, their extracranial lesions remained PD in 12 cases (80%) ( Table 2 ). In other words, of 40 patients, 26 had comparable responses in both intracranial and extracranial diseases, including 14 whose 2 disease sites achieved DC and 12 whose 2 disease sites showed progression, whereas differential response was observed in 14 patients (ie, intracranial SD and extracranial PD, or vice versa) ( Table 2 ). In our series, there were no clinical factors affecting the response of either intracranial or extracranial diseases to erlotinib (all P > 0.05). DCR within the brain lesions in patients with activating EGFR mutations was 80% (1 PR+3 SDs), compared with 25% (1 SD) in those with negative EGFR mutation. 
Survival Data
Follow-up was terminated on December 31, 2010. At the time of the data cut off, 34 patients had died, and 6 survived; 2 of whom were free of disease progression and still on erlotinib.
In the current study, the median PFS was 3.0 months (95% CI, 2.0-4.0 mo) ( Fig. 1) ; the median survival was 9.2 months (95% CI, 4.2-14.2 mo) ( Fig. 2) . Univariate analysis showed that smoking history, PS, RPA class, and DCR in the brain were related to survival, whereas only the factor of DCR in the brain had statistical significance in multivariate analysis (Table 3 ).
Toxicity
All patients were included in the toxicity analysis. Of the 40 patients, 29 (72.5%) had at least one type of drug-related toxicity; rash was found in 20 patients (69%), followed by diarrhea in 11 patients (38%). Other toxicities included fatigue (24.1%), loss of appetite (17.2%), nausea (13.8%), hepatotoxicity (10.3%), nail disorders (6.9%), and vomiting (3.4%). Side effects were mild to moderate (grade 1 to 2), and no grade 3 to 4 toxicities were recorded. No interstitial lung disease-type event was encountered, and no patient stopped erlotinib due to intolerable side effects.
DISCUSSION
Brain metastases are common in NSCLC and are usually associated with poor prognosis. A survival plateau has been reached with regard to the traditionally used therapeutic interventions for brain metastases, and new treatment strategies are definitely required. Strong interest is now focused on the use of EGFR-TKIs for the therapy of brain metastases from NSCLC.
On the basis of the results of several clinical trials, erlotinib has been proved effective in modest improvements with survival for refractory NSCLC patients after failure in previous chemotherapy. In a phase II trial of erlotinib in NSCLC, ORR and DCR were 12.3% and 51.3%, respectively, with a median survival of 8.4 months and a 1-year survival rate of 40%. 17 The pivotal BR.21 study was the first randomized trial of EGFR-TKI demonstrating substantial survival benefit in NSCLC. In the BR.21 study of patients treated with erlotinib, ORR and DCR were 8.9% and 45%, respectively, with a median PFS of 2.4 months, median survival of 6.7 months, and a 1-year survival rate of 31.2%. 10 In a phase IV trial of erlotinib in NSCLC, ORR and DCR were 9% and 63%, respectively, with a median PFS of 15 weeks. 18 However, NSCLC patients with brain metastases were excluded in such clinical trials, and there was no specific analysis of this subgroup. Data from large series of brain metastases patients treated with erlotinib are lacking. Erlotinib with a small molecular weight could partly cross the bloodbrain barrier with improved penetration into the CNS and thus has the potential to be active against brain lesions. 19, 20 Therefore, it is logical to study the efficacy of this agent in the treatment for NSCLC with brain metastases. This study showed an ORR of 10% and a DCR of 62.5% within brain lesions after failure in previous application of intracranial irradiation and chemotherapy, with a median PFS of 3.0 months and median survival of 9.2 months, respectively. Our data confirmed the effect with the use of erlotinib on recurrent or progressive brain metastases from NSCLC, an observation that supported the results of some individual case or small sample series reports (Table 4 ). [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In this regard, it has been speculated that erlotinib may provide clinical benefits in this patient population, which could supplement the traditional treatment and prolong the survival.
To date, less information has been available in some case reports about whether there was any correlation between the efficacy of erlotinib for brain metastases and extracranial diseases. [22] [23] [24] [25] [26] [27] [28] In our cohort, the DCR of erlotinib was higher in intracranial diseases than in extracranial diseases (62.5% vs. 42.5%). Moreover, parallel and differential response was observed in 26 (65%) and 14 (35%) patients, respectively. Particularly, the patients whose intracranial lesions showed progression were highly likely to remain PD in extracranial lesions on erlotinib therapy; however, as for the patients whose intracranial lesions had disease control, only about half them achieved PR/SD in extracranial lesions. In contrast, of 17 patients with extracranial PR/SD, only 3 (18%) had disease progression in the brain. It seemed that if patients were destined to have a PR/SD in extracranial sites, there was a low likelihood that the disease would progress in the brain. The reason why the intracranial response to erlotinib was not consistent with extracranial response is currently unexplained and further studies are recommended.
Generally, erlotinib does not have the severe systemic side effects usually seen with cytotoxic drugs and is well tolerated with most adverse events being of mild-to-moderate severity. 10, 17, 18 In our series, the most frequent toxicities were rash and diarrhea with grade 1 to 2 severity; no patient dis-continued erlotinib because of these side effects. Our data demonstrated that erlotinib was well tolerated; supportive care without dose reduction or drug withdrawal was adequate to remedy toxicities.
It is now well known that EGFR-TKIs are more efficacious in patients whose tumors harbour activating EGFR mutations and those patients also have a longer survival. [32] [33] [34] [35] [36] However, the efficacy of erlotinib in brain metastases and its association with EGFR mutation has been seldom described. Our data revealed that DCR within the brain lesions was higher in EGFR-mutant patients than nonmutant ones (83.3% vs. 20%). Erlotinib seemed to be more effective in brain metastases from NSCLC with activating EGFR mutations, which was in agreement with the results from some small sample series reports. [25] [26] [27] [28] [29] [30] [31] It suggested a possible correlation between EGFR mutations and the efficacy of erlotinib in treatment for brain metastases, but the number of the mutation-examined patients was too small to allow statistically sound conclusion of such in this study. Ideally, the data about EGFR mutation status should be available for all (or most) patients included in this study, so that more accurate conclusions could be made as to whether erlotinib helps brain metastases, but it is unlikely that such an assessment would have been performed on the earlier patients. As noted, EGFR mutations are often found in nonsmokers, adenocarcinoma, females, and Asians, 37-40 possibly explaining the association of these clinical characteristics with response to EGFR-TKI treatment; but there was a higher percentage of patients studied being males (85%) and smokers (62.5%) in this group, which would predict a lower frequency of activating EGFR mutations. This may impact on the results, because one would anticipate the more dramatic CNS responders to EGFR-TKIs to be those who harbour sensitizing EGFR mutations. Especially, the mutational analysis was performed in initially surgical lung tumor specimens, whereas erlotinib was given to patients after intracranial irradiation and multiple courses of chemotherapy. As such, the EGFR mutation status in brain metastases may not be the same as that in the primary lung tumor and may account for some mutationpositive unresponsive cases. Therefore, it is improper to draw any definitive conclusion from our data. Nevertheless, it is not inconceivable to think that intracranial lesions can achieve high response to erlotinib in a molecularly selected population, which may be indicative of possible outcomes that should be evaluated in later studies. Several clinical trials have indicated that some NSCLC patient subgroups (nonsmokers, adenocarcinoma, females, and Asians) are expected to achieve higher responses to EGFR-TKI and have survival advantages. [8] [9] [10] 18, 41 In contrast, our study showed that there were no clinical factors associated with response to erlotinib and the patients' survival as well, whereas the DCR in the brain was the only favourable prognostic factor for survival. In our opinion, these discrepancies possibly result from several factors: first, the current study in a single institution was retrospective one involved a limited sample size of only 40 patients with heterogeneous baseline characteristics; second, the patients enrolled specifically suffered from brain metastases, a disease with many unique features; third, this was an unselected population on the basis of molecular markers. With this in mind, we should take extra precautions in interpreting the present data.
In conclusion, erlotinib seems to be an attractive alternative to conventional therapies for treating patients with brain metastases of NSCLC. Erlotinib seems to be more effective in patients with activating EGFR mutations. Further randomized, controlled, and prospective trials are warranted to clarify the role of erlotinib in this clinical setting.
